TY - JOUR
T1 - Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant
AU - Chowdhury, Sharmin Reza
AU - Gu, Jinxin
AU - Hu, Yixin
AU - Wang, Juntao
AU - Lei, Shuwen
AU - Tavallaie, Mojdeh S.
AU - Lam, Celine
AU - Lu, Dan
AU - Jiang, Faqin
AU - Fu, Lei
N1 - Publisher Copyright:
© 2021 Elsevier Masson SAS
PY - 2021/10/15
Y1 - 2021/10/15
N2 - A series of benzofuran piperidine derivatives were designed, synthesized and evaluated as multifunctional Aβ antiaggregant to treat Alzheimer's disease (AD). In vitro results revealed that all of them are very good Aβ antiaggregants and some of the compounds are potent acetylcholinesterase (AChE) inhibitors with moderate antioxidant property. Selected compounds were also tested for neuroprotection activity, LDH release, ATP production and inhibitory activity to prevent Aβ peptides binding to the cell membrane. The different modifications introduced in the structure of our lead compound 3 (hAChE IC50 = 61 μM and self induced Aβ 25-35 aggregation 45.45%), to increase its activity toward AD related targets. The most interesting multifunctional Aβ antiaggregants were compounds 3a, 3h and 3i, highlighting 3h as potent Aβ antiaggregant and good antiacetylholinesterase inhibitor (self induced Aβ 25-35 aggregation 57.71% and hAChE IC50 = 21 μM), with good neuroprotective and antioxidant activity. In addition, these three most promising compounds prevent intracellular reactive oxygen species (ROS) formation and cell apoptosis induced by Aβ25-35 peptides in SH-SY5Y cells. Molecular docking studies were also accomplished to understand the binding interaction of these compounds on Aβ monomer, Aβ fibril and AChE. Based on all data, compounds 3a, 3h and 3i were concluded as potent multifunctional Aβ antiaggregant, useful candidate for the treatment of AD.
AB - A series of benzofuran piperidine derivatives were designed, synthesized and evaluated as multifunctional Aβ antiaggregant to treat Alzheimer's disease (AD). In vitro results revealed that all of them are very good Aβ antiaggregants and some of the compounds are potent acetylcholinesterase (AChE) inhibitors with moderate antioxidant property. Selected compounds were also tested for neuroprotection activity, LDH release, ATP production and inhibitory activity to prevent Aβ peptides binding to the cell membrane. The different modifications introduced in the structure of our lead compound 3 (hAChE IC50 = 61 μM and self induced Aβ 25-35 aggregation 45.45%), to increase its activity toward AD related targets. The most interesting multifunctional Aβ antiaggregants were compounds 3a, 3h and 3i, highlighting 3h as potent Aβ antiaggregant and good antiacetylholinesterase inhibitor (self induced Aβ 25-35 aggregation 57.71% and hAChE IC50 = 21 μM), with good neuroprotective and antioxidant activity. In addition, these three most promising compounds prevent intracellular reactive oxygen species (ROS) formation and cell apoptosis induced by Aβ25-35 peptides in SH-SY5Y cells. Molecular docking studies were also accomplished to understand the binding interaction of these compounds on Aβ monomer, Aβ fibril and AChE. Based on all data, compounds 3a, 3h and 3i were concluded as potent multifunctional Aβ antiaggregant, useful candidate for the treatment of AD.
KW - Alzheimer's disease
KW - Anti acetylcholinesterase
KW - Aβ antiaggregant
KW - Benzofuran piperidine
KW - Neuroprotective
UR - http://www.scopus.com/inward/record.url?scp=85107639131&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2021.113541
DO - 10.1016/j.ejmech.2021.113541
M3 - Article
C2 - 34116326
AN - SCOPUS:85107639131
SN - 0223-5234
VL - 222
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 113541
ER -